NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-06-30Est. Completion: 2033-03-23

Enrollment target: 2,400 participants

Locations

Banner MD Anderson Cancer Center ( Site 0066), Gilbert, Arizona, United States
Mayo Clinic Cancer Center ( Site 0034), Phoenix, Arizona, United States
University of Arizona Cancer Center ( Site 0035), Tucson, Arizona, United States
Roy and Patricia Disney Family Cancer Center ( Site 0055), Burbank, California, United States
Providence Medical Foundation ( Site 0080), Fullerton, California, United States
Hoag Memorial Hospital Presbyterian ( Site 0010), Newport Beach, California, United States
Helios Clinical Research ( Site 0061), Whittier, California, United States
Intermountain Health Cancer Center Saint Joseph ( Site 0062), Denver, Colorado, United States
Rocky Mountain Cancer Centers (RMCC) ( Site 8006), Denver, Colorado, United States
Intermountain Health St. Mary's Regional Hospital ( Site 0054), Grand Junction, Colorado, United States
AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044), Altamonte Springs, Florida, United States
Florida Cancer Specialists - South ( Site 7004), Fort Myers, Florida, United States
Bioresearch Partner ( Site 0072), Hialeah, Florida, United States

Breast CancerAnthracycline Related Cardiotoxicity in Breast CancerVirtual RealityTrastuzumab

The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experienc…

Richmond, United StatesEst. completion Jul 30, 2026

Early Breast Cancer

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant g…

Daphne, United StatesEst. completion Aug 8, 2025

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.